181 related articles for article (PubMed ID: 33712534)
1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of
Marchetti L; Perrucci L; Pellegrino F; Baroni L; Merlo A; Tilli M; Rambaldi I; Maietti E; Carnevale A; Bartolomei M; Giganti M
J Nucl Med; 2021 Oct; 62(10):1372-1379. PubMed ID: 33712534
[TBL] [Abstract][Full Text] [Related]
2. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
Gómez León N; Delgado-Bolton RC; Del Campo Del Val L; Cabezas B; Arranz R; García M; Cannata J; González Ortega S; Pérez Sáez MÁ; López-Botet B; Rodríguez-Vigil B; Mateo M; Colletti PM; Rubello D; Carreras JL
Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
[TBL] [Abstract][Full Text] [Related]
4. Comparison of
Panebianco M; Bagni O; Cenfra N; Mecarocci S; Ortu La Barbera E; Filippi L; Codacci-Pisanelli G; Biondi T; Laghi A; Cimino G
Leuk Res; 2019 Jan; 76():48-52. PubMed ID: 30553980
[TBL] [Abstract][Full Text] [Related]
5. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
[TBL] [Abstract][Full Text] [Related]
6. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
7. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of
Tsuyoshi H; Tsujikawa T; Yamada S; Okazawa H; Yoshida Y
Cancer Imaging; 2020 Oct; 20(1):75. PubMed ID: 33092631
[TBL] [Abstract][Full Text] [Related]
9. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
Nayak B; Dogra PN; Naswa N; Kumar R
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.
Altini C; Niccoli Asabella A; Di Palo A; Fanelli M; Ferrari C; Moschetta M; Rubini G
Medicine (Baltimore); 2015 May; 94(20):e864. PubMed ID: 25997066
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A;
Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534
[TBL] [Abstract][Full Text] [Related]
13. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
14. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.
Pfluger T; Melzer HI; Schneider V; La Fougere C; Coppenrath E; Berking C; Bartenstein P; Weiss M
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):822-31. PubMed ID: 21210112
[TBL] [Abstract][Full Text] [Related]
15. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.
Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L; Madero R
J Nucl Med; 2006 Oct; 47(10):1643-8. PubMed ID: 17015900
[TBL] [Abstract][Full Text] [Related]
16. Value of FDG PET/Contrast-Enhanced CT in Initial Staging of Colorectal Cancer - Comparison with Contrast-Enhanced CT.
Kunawudhi A; Sereeborwornthanasak K; Promteangtrong C; Siripongpreeda B; Vanprom S; Chotipanich C
Asian Pac J Cancer Prev; 2016; 17(8):4071-5. PubMed ID: 27644663
[TBL] [Abstract][Full Text] [Related]
17. [Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer.].
Altini C; Niccoli Asabella A; Lavelli V; Bianco G; Ungaro A; Pisani A; Merenda N; Ferrari C; Rubini G
Recenti Prog Med; 2019 Mar; 110(3):144-150. PubMed ID: 30968855
[TBL] [Abstract][Full Text] [Related]
18. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.
Moon SH; Cho SK; Kim WS; Kim SJ; Chan Ahn Y; Choe YS; Lee KH; Kim BT; Choi JY
J Nucl Med; 2013 Jul; 54(7):1039-44. PubMed ID: 23658217
[TBL] [Abstract][Full Text] [Related]
19. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma?
Perlaza P; Ortín J; Pagès M; Buxó E; Fernández-Esparrach G; Colletti PM; Rubello D; Mayoral M; Sánchez N; Ruiz C; Ginés A; Fuster D
Clin Nucl Med; 2018 Jun; 43(6):402-410. PubMed ID: 29485442
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 18F-labelled fluoro-2-deoxyglucose-PET with conventional computed tomography for staging and response assessment in paediatric and adult patients with nodular lymphocyte-predominant Hodgkin's lymphoma.
Rauf MS; Khan ZA; Zahir MN; Al-Sweedan S; Al-Kofide A; Alharthy H; Almugbel FA; Osmani A; Elhassan TAM; Khafaga Y; Maghfoor I; Akhtar S
Nucl Med Commun; 2021 Aug; 42(8):899-906. PubMed ID: 33852535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
